Search - tctmd.com

Displaying 241 - 260 of 900

Sort: Relevancy | Date

Presentation TCT 2018

Clinical Trials for Short DAPT: FDA Perspective

Presenter: Christopher J Popma

September 22, 2018

Presentation TCT 2018

The Current Situation of DAPT for Coronary DES in US

Presenter: Mitchell W. Krucoff

September 22, 2018

Presentation TCT 2018

The Current Situation of DAPT for Coronary DES in Japan

Presenter: Hiroyoshi Yokoi

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2018

TCT-110: Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry

Presenter: George D. Dangas, Germano Di Sciascio, Kamilia Moalem

September 21, 2018

Presentation TCT 2018

Does Aspirin Have a Role in the Management of Patients Undergoing PCI?

Presenter: Jeroen J. Bax, Stephan Windecker, Patrick W. Serruys

September 21, 2018

Presentation TCT 2018

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

Presenter: Jeroen J. Bax, Stephan Windecker

September 21, 2018

Presentation

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

July 11, 2018

Presentation

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

May 21, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

Presenter: Allen Jeremias

May 06, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Presenter: Rasha Al-Lamee

May 05, 2018

Presentation

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

April 17, 2018

Presentation Fellows 2018

ACS Pharmacology for the Interventionalist

Presenter: Duane S. Pinto, Gregg W. Stone

April 13, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Advertisement

Clinical Trials for Short DAPT: FDA Perspective

The Current Situation of DAPT for Coronary DES in US

The Current Situation of DAPT for Coronary DES in Japan

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

TCT-110: Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry

Does Aspirin Have a Role in the Management of Patients Undergoing PCI?

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

ACS Pharmacology for the Interventionalist

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content